Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis. The company's products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral Medical Inc., formerly known as Spectral Diagnostics Inc., is headquartered in Toronto, Canada.
| Revenue (Most Recent Fiscal Year) | $1.67M |
| Net Income (Most Recent Fiscal Year) | $-11.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 137.14 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -832.51% |
| Net Margin (Trailing 12 Months) | -1538.72% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -836.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.11 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 4.40 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 289.16M |
| Free Float | 284.82M |
| Market Capitalization | $265.65M |
| Average Volume (Last 20 Days) | 7948.40 |
| Beta (Past 60 Months) | 0.09 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |